Results 41 to 50 of about 40,749 (237)

Premature Mortality in Patients With Anorexia Nervosa: A Matched Cohort Study of Cause of Death

open access: yesInternational Journal of Eating Disorders, EarlyView.
ABSTRACT Objective To determine the extent to which anorexia nervosa is associated with premature mortality. Method We carried out a matched cohort study of 7332 male and female patients with anorexia nervosa and 73,215 patient controls who were admitted between 1989 and 2023 in hospital centers of Quebec, Canada. We tracked the patients longitudinally
Nathalie Auger   +7 more
wiley   +1 more source

A SLC16A1 Mutation in an Infant With Ketoacidosis and Neuroimaging Assessment: Expanding the Clinical Spectrum of MCT1 Deficiency

open access: yesFrontiers in Pediatrics, 2019
The solute carrier family 16 member 1 (SLC16A1) gene encodes for monocarboxylate transporter 1 (MCT1) that mediates the movement of monocarboxylates, such as lactate and pyruvate across cell membranes.
Sara Al-Khawaga   +12 more
doaj   +1 more source

Clinical and Diagnostic Aspects of Diabetic Ketoacidosis

open access: yesMìžnarodnij Endokrinologìčnij Žurnal, 2016
Background. Leading criteria for laboratory diagnosis and determination of diabetic ketoacidosis severity are considered to be the levels of glucose, blood pH and blood bicarbonate.
Z.P. Nizhynska-Аstapenko   +1 more
doaj   +1 more source

Randomized trial to assess worsening renal function by adding dapagliflozin for acute decompensated heart failure

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Dapagliflozin (DAPA), a sodium‐glucose co‐transporter 2 inhibitor, has been shown to reduce cardiovascular mortality among patients with chronic heart failure. We aimed to evaluate the impact on a worsening renal function (WRF) by adding DAPA as compared to standard decongestive therapy with loop diuretics alone.
Shodai Kawanami   +11 more
wiley   +1 more source

Alarming Increase of Ketoacidosis Prevalence at Type 1 Diabetes-Onset in Austria—Results From a Nationwide Registry

open access: yesFrontiers in Pediatrics, 2022
ObjectiveWe analyzed the annual prevalence of onset-DKA (diabetic ketoacidosis) from 2012 to 2020 with a sub-analysis for lockdown-periods during the COVID-19 pandemic in 2020.DesignAll newly diagnosed children with type 1 diabetes (T1D) aged <15 ...
Katrin Nagl   +7 more
doaj   +1 more source

The efficacy and safety of sodium‐glucose cotransporter 2 inhibitors in patients aged over 80 years with heart failure

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Sodium‐glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) have demonstrated effectiveness in reducing cardiovascular death and heart failure hospitalization (HFH). However, the efficacy and safety of SGLT2 inhibitors in elderly patients with poor general status, such as very low bodyweight or low nutritional status, who are not included ...
Kenji Nakano   +15 more
wiley   +1 more source

Rhino-Orbital Cerebral Mucormycosis in a Patient With Diabetic Ketoacidosis: A Case Report and Literature Review

open access: yesFrontiers in Neurology, 2022
BackgroundRhino-orbital cerebral mucormycosis (ROCM) is a rare, invasive, and fatal fungal disease. Due to the lack of specific clinical manifestations and adequate auxiliary examinations, patients are easily misdiagnosed in the early stage.
Nan Dong   +9 more
doaj   +1 more source

Outcomes of Acute Invasive Fungal Rhinosinusitis Patients Treated with Retrobulbar Amphotericin B Injections versus Orbital Exenteration

open access: yes
International Forum of Allergy &Rhinology, EarlyView.
Jakob L. Fischer   +12 more
wiley   +1 more source

Early administration of SGLT2 inhibitors in hospitalized patients: A practical guidance from the current evidence

open access: yesESC Heart Failure, EarlyView.
Abstract Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors represent one of the main cornerstones of heart failure treatment. Nevertheless, while the cardiovascular beneficial effects of these drugs have been clearly demonstrated by several clinical trials, in clinical practice, it remains challenging to identify the appropriate timing to start SGLT2 ...
Ruggero Mazzotta   +10 more
wiley   +1 more source

Characterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART‐FID

open access: yesEuropean Journal of Heart Failure, EarlyView.
Changes in serum phosphate levels over time with ferric carboxymaltose (FCM) in a randomized, double‐blind, prospective substudy of HEART‐FID assessing the following outcomes: serum phosphate, 1,25 dihydroxyvitamin D, 25‐hydroxyvitamin D levels and plasma levels of intact parathyroid hormone during 6 months subsequent to FCM infusion.
Nina Nouhravesh   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy